Abstract
The neurohypophyseal hormone oxytocin (OT) and related modulators of the oxytocin receptor (OTR) have been the subject of intensive research for nearly seven decades. Despite having rather poor drug-like properties, OT is used as a treatment for labor induction, postpartum hemorrhage, and lactation support. The potential use of OT in the treatment of central nervous system (CNS)-related diseases has recently renewed interest in the pharmacology of OT. Oxytocin is one of the most extensively studied cyclic peptides and since the elucidation of its structure in 1953 thousands of peptidic OT analogs with antagonistic and agonistic properties have been synthesized and biologically evaluated. Among them are atosiban, a mixed oxytocin receptor (OTR)/vasopressin 1a receptor (V1aR) antagonist used as a tocolytic agent approved (in certain countries), and carbetocin, a longer acting OTR agonist on the market for the treatment of postpartum hemorrhage. Many other OT analogs with improved pharmacological properties (e.g., barusiban, Antag III) have been identified. These peptides have been tested in clinical trials and/or used as pharmacological tools. In this chapter, the modifications of the OT molecule that led to the discovery of these compounds are reviewed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Gimpl G, Fahrenholz F (2001) The oxytocin receptor system: structure, function, and regulation. Physiol Rev 81(2):629–683
Zingg HH, Laporte SA (2003) The oxytocin receptor. Trends Endocrinol Metab 14(5):222–227
Kimura T, Saji F, Nishimori K et al (2003) Molecular regulation of the oxytocin receptor in peripheral organs. J Mol Endocrinol 30(2):109–115
Baribeau DA, Anagnostou E (2015) Oxytocin and vasopressin: linking pituitary neuropeptides and their receptors to social neurocircuits. Front Neurosci 9:335. https://doi.org/10.3389/fnins.2015.00335
Veening JG, de Jong T, Barendregt HP (2010) Oxytocin-messages via the cerebrospinal fluid: behavioral effects; a review. Physiol Behav 101(2):193–210. https://doi.org/10.1016/j.physbeh.2010.05.004
Ohlsson B, Truedsson M, Djerf P et al (2006) Oxytocin is expressed throughout the human gastrointestinal tract. Regul Pept 135(1–2):7–11. https://doi.org/10.1016/j.regpep.2006.03.008
Gutkowska J, Jankowski M, Lambert C et al (1997) Oxytocin releases atrial natriuretic peptide by combining with oxytocin receptors in the heart. Proc Natl Acad Sci U S A 94(21):11704–11709
Colaianni G, Sun L, Zaidi M et al (2014) Oxytocin and bone. Am J Physiol Regul Integr Comp Physiol 307(8):R970–R977. https://doi.org/10.1152/ajpregu.00040.2014
Shyken JM, Petrie RH (1995) Oxytocin to induce labor. Clin Obstet Gynecol 38(2):232–245
Lawson EA (2017) The effects of oxytocin on eating behaviour and metabolism in humans. Nat Rev Endocrinol 13(12):700–709. https://doi.org/10.1038/nrendo.2017.115
Spetter MS, Hallschmid M (2017) Current findings on the role of oxytocin in the regulation of food intake. Physiol Behav 176:31–39. https://doi.org/10.1016/j.physbeh.2017.03.007
Leng G, Sabatier N (2017) Oxytocin—the sweet hormone? Trends Endocrinol Metab 28(5):365–376. https://doi.org/10.1016/j.tem.2017.02.007
Sun L, Tamma R, Yuen T et al (2016) Functions of vasopressin and oxytocin in bone mass regulation. Proc Natl Acad Sci U S A 113(1):164–169. https://doi.org/10.1073/pnas.1523762113
Yuen T, Sun L, Liu P et al (2016) Beyond reproduction: pituitary hormone actions on bone. Prog Mol Biol Transl Sci 143:175–185. https://doi.org/10.1016/bs.pmbts.2016.08.004
Amri EZ, Pisani DF (2016) Control of bone and fat mass by oxytocin. Horm Mol Biol Clin Investig 28(2):95–104. https://doi.org/10.1515/hmbci-2016-0045
Blevins JE, Baskin DG (2015) Translational and therapeutic potential of oxytocin as an anti-obesity strategy: insights from rodents, nonhuman primates and humans. Physiol Behav 152(Pt B):438–449. https://doi.org/10.1016/j.physbeh.2015.05.023
Blevins JE, Graham JL, Morton GJ et al (2015) Chronic oxytocin administration inhibits food intake, increases energy expenditure, and produces weight loss in fructose-fed obese rhesus monkeys. Am J Physiol Regul Integr Comp Physiol 308(5):R431–R438. https://doi.org/10.1152/ajpregu.00441.2014
Gutkowska J, Jankowski M (2012) Oxytocin revisited: its role in cardiovascular regulation. J Neuroendocrinol 24(4):599–608. https://doi.org/10.1111/j.1365-2826.2011.02235.x
Jankowski M, Broderick TL, Gutkowska J (2016) Oxytocin and cardioprotection in diabetes and obesity. BMC Endocr Disord 16(1):34. https://doi.org/10.1186/s12902-016-0110-1
Motta-Mena NV, Puts DA (2017) Endocrinology of human female sexuality, mating, and reproductive behavior. Horm Behav 91:19–35. https://doi.org/10.1016/j.yhbeh.2016.11.012
Zik JB, Roberts DL (2015) The many faces of oxytocin: implications for psychiatry. Psychiatry Res 226(1):31–37. https://doi.org/10.1016/j.psychres.2014.11.048
Veening JG, de Jong TR, Waldinger MD et al (2015) The role of oxytocin in male and female reproductive behavior. Eur J Pharmacol 753:209–228. https://doi.org/10.1016/j.ejphar.2014.07.045
Stoop R (2014) Neuromodulation by oxytocin and vasopressin in the central nervous system as a basis for their rapid behavioral effects. Curr Opin Neurobiol 29:187–193. https://doi.org/10.1016/j.conb.2014.09.012
Neumann ID, Slattery DA (2015) Oxytocin in general anxiety and social fear: a translational approach. Biol Psychiatry 79(3):213–221. https://doi.org/10.1016/j.biopsych.2015.06.004
Xin Q, Bai B, Liu W (2017) The analgesic effects of oxytocin in the peripheral and central nervous system. Neurochem Int 103:57–64. https://doi.org/10.1016/j.neuint.2016.12.021
Boll S, Almeida de Minas AC, Raftogianni A et al (2017) Oxytocin and pain perception: from animal models to human research. Neuroscience. https://doi.org/10.1016/j.neuroscience.2017.09.041
Wei SQ, Luo ZC, Qi HP et al (2010) High-dose vs. low-dose oxytocin for labor augmentation: a systematic review. Am J Obstet Gynecol 203(4):296–304. https://doi.org/10.1016/j.ajog.2010.03.007
Page K, McCool WF, Guidera M (2017) Examination of the pharmacology of oxytocin and clinical guidelines for use in labor. J Midwifery Women’s Health 62(4):425–433. https://doi.org/10.1111/jmwh.12610
Wing DA, Sheibani L (2015) Pharmacotherapy options for labor induction. Expert Opin Pharmacother 16(11):1657–1668. https://doi.org/10.1517/14656566.2015.1060960
Sentilhes L, Merlot B, Madar H et al (2016) Postpartum haemorrhage: prevention and treatment. Expert Rev Hematol 9(11):1043–1061. https://doi.org/10.1080/17474086.2016.1245135
Ruis H, Rolland R, Doesburg W et al (1981) Oxytocin enhances onset of lactation among mothers delivering prematurely. Br Med J (Clin Res Ed) 283(6287):340–342
Fewtrell MS, Loh KL, Blake A et al (2006) Randomised, double blind trial of oxytocin nasal spray in mothers expressing breast milk for preterm infants. Arch Dis Child Fetal Neonatal Ed 91(3):F169–F174. https://doi.org/10.1136/adc.2005.081265
Kosfeld M, Heinrichs M, Zak PJ et al (2005) Oxytocin increases trust in humans. Nature 435(7042):673–676. https://doi.org/10.1038/nature03701
Feifel D (2011) Is oxytocin a promising treatment for schizophrenia? Expert Rev Neurother 11(2):157–159. https://doi.org/10.1586/ern.10.199
Guastella AJ, Hickie IB (2016) Oxytocin treatment, circuitry, and autism: a critical review of the literature placing oxytocin into the autism context. Biol Psychiatry 79(3):234–242. https://doi.org/10.1016/j.biopsych.2015.06.028
Lee MR, Rohn MC, Tanda G et al (2016) Targeting the oxytocin system to treat addictive disorders: rationale and progress to date. CNS Drugs 30(2):109–123. https://doi.org/10.1007/s40263-016-0313-z
Zanos P, Georgiou P, Weber C et al (2017) Oxytocin and opioid addiction revisited: old drug, new applications. Br J Pharmacol. https://doi.org/10.1111/bph.13757
Bowen MT, Neumann ID (2017) Rebalancing the addicted brain: oxytocin interference with the neural substrates of addiction. Trends Neurosci 40(12):691–708. https://doi.org/10.1016/j.tins.2017.10.003
Tracy LM, Georgiou-Karistianis N, Gibson SJ et al (2015) Oxytocin and the modulation of pain experience: implications for chronic pain management. Neurosci Biobehav Rev 55:53–67. https://doi.org/10.1016/j.neubiorev.2015.04.013
Goodin BR, Ness TJ, Robbins MT (2015) Oxytocin—a multifunctional analgesic for chronic deep tissue pain. Curr Pharm Des 21(7):906–913
Frijling JL, van Zuiden M, Koch SB et al (2014) Efficacy of oxytocin administration early after psychotrauma in preventing the development of PTSD: study protocol of a randomized controlled trial. BMC Psychiatry 14:92. https://doi.org/10.1186/1471-244X-14-92
Shilling PD, Feifel D (2016) Potential of oxytocin in the treatment of schizophrenia. CNS Drugs 30(3):193–208. https://doi.org/10.1007/s40263-016-0315-x
Feifel D, Shilling PD, MacDonald K (2016) A review of oxytocin's effects on the positive, negative, and cognitive domains of schizophrenia. Biol Psychiatry 79(3):222–233. https://doi.org/10.1016/j.biopsych.2015.07.025
Einfeld SL, Smith E, McGregor IS et al (2014) A double-blind randomized controlled trial of oxytocin nasal spray in Prader-Willi syndrome. Am J Med Genet A 164A(9):2232–2239. https://doi.org/10.1002/ajmg.a.36653
Kim S, Soeken TA, Cromer SJ et al (2014) Oxytocin and postpartum depression: delivering on what's known and what's not. Brain Res 1580:219–232. https://doi.org/10.1016/j.brainres.2013.11.009
Brummelte S, Galea LA (2016) Postpartum depression: etiology, treatment and consequences for maternal care. Horm Behav 77:153–166. https://doi.org/10.1016/j.yhbeh.2015.08.008
Tampi RR, Maksimowski M, Ahmed M et al (2017) Oxytocin for frontotemporal dementia: a systematic review. Ther Adv Psychopharmacol 7(1):48–53. https://doi.org/10.1177/2045125316672574
Horta de Macedo LR, Zuardi AW, Machado-de-Sousa JP et al (2014) Oxytocin does not improve performance of patients with schizophrenia and healthy volunteers in a facial emotion matching task. Psychiatry Res 220(1–2):125–128. https://doi.org/10.1016/j.psychres.2014.07.082
Guastella AJ, Gray KM, Rinehart NJ et al (2014) The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. J Child Psychol Psychiatry 56(4):444–452. https://doi.org/10.1111/jcpp.12305
du Vigneaud V, Ressler C, Trippett S (1953) The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin. J Biol Chem 205(2):949–957
du Vigneaud V, Ressler C, Swan JM et al (1953) The synthesis of an octapeptide amide with the hormonal activity of oxytocin. J Am Chem Soc 75:4879–4880
Gimpl G, Reitz J, Brauer S et al (2008) Oxytocin receptors: ligand binding, signalling and cholesterol dependence. Prog Brain Res 170:193–204. https://doi.org/10.1016/S0079-6123(08)00417-2
Hawtin SR, Howard HC, Wheatley M (2001) Identification of an extracellular segment of the oxytocin receptor providing agonist-specific binding epitopes. Biochem J 354(Pt 2):465–472
Polacek I, Krejci I, Nesvadba H et al (1970) Action of (1,6-di-alanine)-oxytocin and (1,6-di-serine)-oxytocin on the rat uterus and mammary gland in vitro. Eur J Pharmacol 9(2):239–245. https://doi.org/10.1016/0014-2999(70)90306-7
Manning M, Przybylski JP, Olma A et al (1987) No requirements of cyclic conformation of antagonists in binding to vasopressin receptors. Nature 329(6142):839–840. https://doi.org/10.1038/329839a0
Manning M, Stoev S, Kolodziejczyk A et al (1990) Design of potent and selective linear antagonists of vasopressor (V1-receptor) responses to vasopressin. J Med Chem 33(11):3079–3086
Chini B, Mouillac B, Ala Y et al (1995) Molecular basis for agonist selectivity in the vasopressin/oxytocin receptor family. Adv Exp Med Biol 395:321–328
Akerlund M, Bossmar T, Brouard R et al (1999) Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women. Br J Obstet Gynaecol 106(10):1047–1053
Wisniewski K, Alagarsamy S, Galyean R et al (2014) New, potent, and selective peptidic oxytocin receptor agonists. J Med Chem 57(12):5306–5317. https://doi.org/10.1021/jm500365s
Abdul-Karim R, Assali NS (1961) Renal function in human pregnancy. V. Effects of oxytocin on renal hemodynamics and water and electrolyte excretion. J Lab Clin Med 57:522–532
Ruchala PL, Metheny N, Essenpreis H et al (2002) Current practice in oxytocin dilution and fluid administration for induction of labor. J Obstet Gynecol Neonatal Nurs 31(5):545–550. https://doi.org/10.1111/j.1552-6909.2002.tb00079.x
Seifer DB, Sandberg EC, Ueland K et al (1985) Water intoxication and hyponatremic encephalopathy from the use of an oxytocin nasal spray. A case report. J Reprod Med 30(3):225–228
Ansseau M, Legros JJ, Mormont C et al (1987) Intranasal oxytocin in obsessive-compulsive disorder. Psychoneuroendocrinology 12(3):231–236
Mayer-Hubner B (1996) Pseudotumour cerebri from intranasal oxytocin and excessive fluid intake. Lancet 347(9001):623. https://doi.org/10.1016/S0140-6736(96)91325-2
Hicks C, Ramos L, Reekie T et al (2014) Body temperature and cardiac changes induced by peripherally administered oxytocin, vasopressin and the non-peptide oxytocin receptor agonist WAY 267,464: a biotelemetry study in rats. Br J Pharmacol 171(11):2868–2887. https://doi.org/10.1111/bph.12613
Leake RD, Weitzman RE, Fisher DA (1980) Pharmacokinetics of oxytocin in the human subject. Obstet Gynecol 56(6):701–704
Landgraf R (1985) Plasma oxytocin concentrations in man after different routes of administration of synthetic oxytocin. Exp Clin Endocrinol 85(2):245–248. https://doi.org/10.1055/s-0029-1210444
Thornton S, Davison JM, Baylis PH (1990) Effect of human pregnancy on metabolic clearance rate of oxytocin. Am J Phys 259(1. Pt 2):R21–R24
Lundin S, Broeders A, Ohlin M et al (1993) Pharmacokinetic and pharmacologic properties of antiuterotonic oxytocin analogs in the rat. J Pharmacol Exp Ther 264(2):783–788
Tsujimoto M, Mizutani S, Adachi H et al (1992) Identification of human placental leucine aminopeptidase as oxytocinase. Arch Biochem Biophys 292(2):388–392. https://doi.org/10.1016/0003-9861(92)90007-J
Yamahara N, Nomura S, Suzuki T et al (2000) Placental leucine aminopeptidase/oxytocinase in maternal serum and placenta during normal pregnancy. Life Sci 66(15):1401–1410. https://doi.org/10.1016/S0024-3205(00)00451-3
Gossen A, Hahn A, Westphal L et al (2012) Oxytocin plasma concentrations after single intranasal oxytocin administration—a study in healthy men. Neuropeptides 46(5):211–215. https://doi.org/10.1016/j.npep.2012.07.001
Shen WC (2003) Oral peptide and protein delivery: unfulfilled promises? Drug Discov Today 8(14):607–608
Renukuntla J, Vadlapudi AD, Patel A et al (2013) Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm 447(1–2):75–93. https://doi.org/10.1016/j.ijpharm.2013.02.030
Ferrie JJ, Gruskos JJ, Goldwaser AL et al (2013) A comparative protease stability study of synthetic macrocyclic peptides that mimic two endocrine hormones. Bioorg Med Chem Lett 23(4):989–995. https://doi.org/10.1016/j.bmcl.2012.12.041
Wang J, Yadav V, Smart AL et al (2015) Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs. Mol Pharm 12(3):966–973. https://doi.org/10.1021/mp500809f
Fjellestad-Paulsen A, Soderberg-Ahlm C, Lundin S (1995) Metabolism of vasopressin, oxytocin, and their analogues in the human gastrointestinal tract. Peptides 16(6):1141–1147
Ghezzi P (2013) Protein glutathionylation in health and disease. Biochim Biophys Acta 1830(5):3165–3172. https://doi.org/10.1016/j.bbagen.2013.02.009
Mens WB, Witter A, van Wimersma Greidanus TB (1983) Penetration of neurohypophyseal hormones from plasma into cerebrospinal fluid (CSF): half-times of disappearance of these neuropeptides from CSF. Brain Res 262(1):143–149. https://doi.org/10.1016/0006-8993(83)90478-X
Leng G, Ludwig M (2016) Intranasal oxytocin: myths and delusions. Biol Psychiatry 79(3):243–250. https://doi.org/10.1016/j.biopsych.2015.05.003
Striepens N, Kendrick KM, Hanking V et al (2013) Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans. Sci Rep 3:3440. https://doi.org/10.1038/srep03440
Chang SW, Barter JW, Ebitz RB et al (2012) Inhaled oxytocin amplifies both vicarious reinforcement and self-reinforcement in rhesus macaques (Macaca mulatta). Proc Natl Acad Sci U S A 109(3):959–964. https://doi.org/10.1073/pnas.1114621109
Modi ME, Connor-Stroud F, Landgraf R et al (2014) Aerosolized oxytocin increases cerebrospinal fluid oxytocin in rhesus macaques. Psychoneuroendocrinology 45:49–57. https://doi.org/10.1016/j.psyneuen.2014.02.011
Gard JW, Alexander JM, Bawdon RE et al (2002) Oxytocin preparation stability in several common obstetric intravenous solutions. Am J Obstet Gynecol 186(3):496–498
Kumar V, Madabushi R, Derendorf H et al (2006) Development and validation of an HPLC method for oxytocin in Ringer's Lactate and its application in stability analysis. J Liq Chromatogr Relat Technol 29(16):2353–2365
Trissel LA, Zhang Y, Douglass K et al (2006) Extended stability of oxytocin in common infusion solutions. Int J Pharm Compd 10(2):156–158
Kaushal G, Sayre BE, Prettyman T (2012) Stability-indicating HPLC method for the determination of the stability of oxytocin parenteral solutions prepared in polyolefin bags. Drug Discov Ther 6(1):49–54
Avanti C, Amorij JP, Setyaningsih D et al (2011) A new strategy to stabilize oxytocin in aqueous solutions: I. The effects of divalent metal ions and citrate buffer. AAPS J 13(2):284–290. https://doi.org/10.1208/s12248-011-9268-7
Avanti C, Permentier HP, Dam A et al (2012) A new strategy to stabilize oxytocin in aqueous solutions: II. Suppression of cysteine-mediated intermolecular reactions by a combination of divalent metal ions and citrate. Mol Pharm 9(3):554–562. https://doi.org/10.1021/mp200622z
Hawe A, Poole R, Romeijn S et al (2009) Towards heat-stable oxytocin formulations: analysis of degradation kinetics and identification of degradation products. Pharm Res 26(7):1679–1688. https://doi.org/10.1007/s11095-009-9878-2
Wisniewski K, Finnman J, Flipo M et al (2013) On the mechanism of degradation of oxytocin and its analogues in aqueous solution. Biopolymers 100(4):408–421. https://doi.org/10.1002/bip.22260
Manning M, Stoev S, Chini B et al (2008) Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res 170:473–512. https://doi.org/10.1016/S0079-6123(08)00437-8
Chini B, Manning M, Guillon G (2008) Affinity and efficacy of selective agonists and antagonists for vasopressin and oxytocin receptors: an “easy guide” to receptor pharmacology. Prog Brain Res 170:513–517. https://doi.org/10.1016/S0079-6123(08)00438-X
Kimura T, Tanizawa O, Mori K et al (1992) Structure and expression of a human oxytocin receptor. Nature 356(6369):526–529. https://doi.org/10.1038/356526a0
Kimura T, Azuma C, Takemura M et al (1993) Molecular cloning of a human oxytocin receptor. Regul Pept 45(1–2):73–77
Thibonnier M, Auzan C, Madhun Z et al (1994) Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. J Biol Chem 269(5):3304–3310
Sugimoto T, Saito M, Mochizuki S et al (1994) Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. J Biol Chem 269(43):27088–27092
Birnbaumer M, Antaramian A, Themmen AP et al (1992) Desensitization of the human V2 vasopressin receptor. Homologous effects in the absence of heterologous desensitization. J Biol Chem 267(17):11783–11788
Lolait SJ, O'Carroll AM, McBride OW et al (1992) Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature 357(6376):336–339. https://doi.org/10.1038/357336a0
Freidinger RM, Pettibone DJ (1997) Small molecule ligands for oxytocin and vasopressin receptors. Med Res Rev 17(1):1–16. https://doi.org/10.1002/(SICI)1098-1128(199701)17:1<1::AID-MED1>3.0.CO;2-5
Borthwick AD (2010) Oral oxytocin antagonists. J Med Chem 53(18):6525–6538. https://doi.org/10.1021/jm901812z
Pitt GR, Batt AR, Haigh RM et al (2004) Non-peptide oxytocin agonists. Bioorg Med Chem Lett 14(17):4585–4589. https://doi.org/10.1016/j.bmcl.2004.04.107
Ring RH, Schechter LE, Leonard SK et al (2010) Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology 58(1):69–77. https://doi.org/10.1016/j.neuropharm.2009.07.016
Blanks AM, Thornton S (2003) The role of oxytocin in parturition. BJOG 110 Suppl 20:46–51
Laudanski T, Pierzynski P (2003) Oxytocin and fetal membranes in preterm labor: current concepts and clinical implication. Gynecol Endocrinol 17(3):261–267
Zeeman GG, Khan-Dawood FS, Dawood MY (1997) Oxytocin and its receptor in pregnancy and parturition: current concepts and clinical implications. Obstet Gynecol 89(5. Pt 2):873–883
Takahashi K, Diamond F, Bieniarz J et al (1980) Uterine contractility and oxytocin sensitivity in preterm, term, and postterm pregnancy. Am J Obstet Gynecol 136(6):774–779. https://doi.org/10.1016/0002-9378(80)90455-X
Kimura T, Takemura M, Nomura S et al (1996) Expression of oxytocin receptor in human pregnant myometrium. Endocrinology 137(2):780–785. https://doi.org/10.1210/endo.137.2.8593830
Schwarz MK, Page P (2003) Preterm labour: an overview of current and emerging therapeutics. Curr Med Chem 10(15):1441–1468
Robinson JN, Regan JA, Norwitz ER (2001) The epidemiology of preterm labor. Semin Perinatol 25(4):204–214
Sawyer WH, Grzonka Z, Manning M (1981) Neurohypophysial peptides. Design of tissue-specific agonists and antagonists. Mol Cell Endocrinol 22(2):117–134. https://doi.org/10.1016/0303-7207(81)90086-1
Lebl M (1987) Analogs with inhibitory properties. In: Jost K, Lebl M, Brtnik F (eds) CRC Handbook of neurohypophyseal hormone analogs, vol 2, pt 1. CRC Press, Boca Raton, pp 17–74
Hruby VJ, Smith CW (1987) Structure-activity relationships of neurohypophyseal peptides. Peptides (N Y) 8:77–207
Manning M, Sawyer WH (1989) Discovery, development, and some uses of vasopressin and oxytocin antagonists. J Lab Clin Med 114(6):617–632
Manning M, Sawyer WH (1993) Design, synthesis and some uses of receptor-specific agonists and antagonists of vasopressin and oxytocin. J Recept Res 13(1–4):195–214
Manning M, Cheng LL, Klis WA et al (1995) Advances in the design of selective antagonists, potential tocolytics, and radioiodinated ligands for oxytocin receptors. Adv Exp Med Biol 395:559–583
Vrachnis N, Malamas FM, Sifakis S et al (2011) The oxytocin-oxytocin receptor system and its antagonists as tocolytic agents. Int J Endocrinol 2011:350546. https://doi.org/10.1155/2011/350546
Manning M, Misicka A, Olma A et al (2012) Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J Neuroendocrinol 24(4):609–628. https://doi.org/10.1111/j.1365-2826.2012.02303.x
Law HD, du Vigneaud V (1960) Synthesis of 2-(p-methoxyphenyl)alanine oxytocin (O-methyloxytocin) and some observations on its pharmacological behavior. J Am Chem Soc 82:4579–4581. https://doi.org/10.1021/ja01502a034
Schulz H, Du Vigneaud V (1966) Synthesis of 1-L-penicillamine-oxytocin, 1-D-penicillamine-oxytocin, and 1-deaminopenicillamine-oxytocin, potent inhibitors of the oxytocic response of oxytocin. J Med Chem 9(5):647–650
Vavrek RJ, Ferger MF, Allen GA et al (1972) Synthesis of three oxytocin analogs related to (1-deaminopenicillamine)oxytocin possessing antioxytocic activity. J Med Chem 15(2):123–126
Nestor JJ Jr, Ferger MF, du Vigneaud V (1975) [1-Beta-mercapto-beta,beta-pentamethylenepropionic acid]oxytocin, a potent inhibitor of oxytocin. J Med Chem 18(3):284–287
Lowbridge J, Manning M, Seto J et al (1979) Synthetic antagonists of in vivo responses by the rat uterus to oxytocin. J Med Chem 22(5):565–569
Sawyer WH, Haldar J, Gazis D et al (1980) The design of effective in vivo antagonists of rat uterus and milk ejection responses to oxytocin. Endocrinology 106(1):81–91. https://doi.org/10.1210/endo-106-1-81
Bankowski K, Manning M, Seto J et al (1980) Design and synthesis of potent in vivo antagonists of oxytocin. Int J Pept Protein Res 16(5):382–391
Kaurov OA, Martynov VF, Mikhailov YD et al (1972) Synthesis of new oxytocin analogs modified in position 2. Zh Obshch Khim 42(7):1654
Kaurov OA, Mikhailov YD, Smirnova MP (1978) Structure-uterotonic activity relationship for oxytocin analogs modified in position 2. Bioorg Khim 4(5):619–627
Lebl M, Barth T, Servitova L et al (1982) Analogs of neurohypophysial hormones containing a D-amino acid in position 2. In: Peptides, Proceedings of the 17th European Peptide Symposium. de Gruyter, Berlin, pp 457–460
Lebl M, Barth T, Servitova L et al (1985) Amino acids and peptides. CXC. Oxytocin analogs with inhibitory properties, containing in position 2 a hydrophobic amino acid of D-configuration. Collect Czechoslov Chem Commun 50(1):132–145. https://doi.org/10.1135/cccc19850132
Chan WY, Rockway TW, Hruby VJ (1987) Long-acting oxytocin antagonists: effects of 2-D-stereoisomer substitution on antagonistic potency and duration of action. Proc Soc Exp Biol Med 185(2):187–192
Flouret G, Brieher W, Mahan K et al (1991) Design of potent oxytocin antagonists featuring D-tryptophan at position 2. J Med Chem 34(2):642–646
Flouret G, Majewski T, Balaspiri L et al (2002) Antagonists of oxytocin featuring replacement with modified beta-mercaptopropionic acids at position 1. J Pept Sci 8(7):314–326. https://doi.org/10.1002/psc.390
Ahn TG, Han SJ, Cho YS et al (2004) In vivo activity of the potent oxytocin antagonist on uterine activity in the rat. In Vivo 18(6):763–766
Fejgin MD, Pak SC, Flouret G et al (1998) Comparison of the in vivo activity of different oxytocin antagonists in the pregnant baboon. J Soc Gynecol Investig 5(5):251–254. https://doi.org/10.1016/S1071-5576(98)00021-5
Song CH, So GY, Pak SC et al (2002) Comparison of oxytocin and oxytocin antagonist metabolism in the plasma of pregnant humans and baboons. Gynecol Obstet Investig 54(1):21–25. https://doi.org/10.1159/000064692
Flouret G, Chaloin O, Slaninova J (2003) Analogues of a potent oxytocin antagonist with truncated C-terminus or shorter amino acid side chain of the basic amino acid at position 8. J Pept Sci 9(6):393–401. https://doi.org/10.1002/psc.471
Flouret G, Chaloin O, Borovickova L et al (2006) Analogues of oxytocin antagonists bearing a ureido group in the amino acid side chain at position 4 or 5. J Pept Sci 12(5):347–353. https://doi.org/10.1002/psc.733
Lebl M, Barth T, Servitova L et al (1984) Amino acids and peptides. CLXXXVI. Synthesis and properties of carba-6 analogs of oxytocin containing a deaminopenicillamine residue in position 1. Collect Czechoslov Chem Commun 49(9):2012–2023. https://doi.org/10.1135/cccc19842012
Prochazka Z, Slaninova J, Barth T et al (1992) Amino acids and peptides. CCXXIX. Analogs of deamino carba oxytocin with inhibitory properties; synthesis and biological activities. Collect Czechoslov Chem Commun 57(6):1335–1344. https://doi.org/10.1135/cccc19921335
Manning M, Cheng LL, Stoev S et al (2005) Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban. J Pept Sci 11(10):593–608. https://doi.org/10.1002/psc.667
Manning M, Kruszynski M, Bankowski K et al (1989) Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin. J Med Chem 32(2):382–391
Magafa V, Borovickova L, Slaninova J et al (2010) Synthesis and biological activity of oxytocin analogues containing unnatural amino acids in position 9: structure activity study. Amino Acids 38(5):1549–1559. https://doi.org/10.1007/s00726-009-0372-2
Breton C, Chellil H, Kabbaj-Benmansour M et al (2001) Direct identification of human oxytocin receptor-binding domains using a photoactivatable cyclic peptide antagonist: comparison with the human V1a vasopressin receptor. J Biol Chem 276(29):26931–26941. https://doi.org/10.1074/jbc.M102073200
Elands J, Barberis C, Jard S et al (1988) 125I-labelled d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH2(9)]OVT: a selective oxytocin receptor ligand. Eur J Pharmacol 147(2):197–207. https://doi.org/10.1016/0014-2999(88)90778-9
Carnazzi E, Aumelas A, Mouillac B et al (2001) Design, synthesis and pharmacological characterization of a potent radioiodinated and photoactivatable peptidic oxytocin antagonist. J Med Chem 44(18):3022–3030
Melin P, Vilhardt H, Lindeberg G et al (1981) Inhibitory effect of O-alkylated analogues of oxytocin and vasopressin on human and rat myometrial activity. J Endocrinol 88(2):173–180
Akerlund M, Kostrzewska A, Laudanski T et al (1983) Vasopressin effects on isolated non-pregnant myometrium and uterine arteries and their inhibition by deamino-ethyl-lysine-vasopressin and deamino-ethyl-oxytocin. Br J Obstet Gynaecol 90(8):732–738
Akerlund M, Stromberg P, Forsling ML et al (1983) Inhibition of vasopressin effects on the uterus by a synthetic analogue. Obstet Gynecol 62(3):309–312
Melin P, Trojnar J, Vilhardt H et al (1983) Uterotonic oxytocin and vasopressin antagonists with minimal structure modifications. In: Hruby VJ, Rich DH (eds) Peptides. Structure and function. Proceedings of the Eight American Peptide Symposium, Tuscon, AZ, USA. Pierce Chem. Co., pp 361–364
Melin P, Trojnar J, Johansson B et al (1986) Synthetic antagonists of the myometrial response to vasopressin and oxytocin. J Endocrinol 111 (1):125–131
Romero R, Sibai BM, Sanchez-Ramos L et al (2000) An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am J Obstet Gynecol 182(5):1173–1183. https://doi.org/10.1067/mob.2000.95834
Valenzuela GJ, Sanchez-Ramos L, Romero R et al (2000) Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. The Atosiban PTL-098 Study Group. Am J Obstet Gynecol 182(5):1184–1190. https://doi.org/10.1067/mob.2000.105816
Tsatsaris V, Carbonne B, Cabrol D (2004) Atosiban for preterm labour. Drugs 64(4):375–382
Husslein P, Quartarolo JP (2003) Review of clinical experience with atosiban and the Tractocile Efficacy Assessment Survey in Europe (TREASURE) study protocol. Int J Clin Pract 57(2):121–127
Manning M, Miteva K, Pancheva S et al (1995) Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban. Int J Pept Protein Res 46(3–4):244–252
Chan WY, Wo NC, Manning M (1996) The role of oxytocin receptors and vasopressin V1a receptors in uterine contractions in rats: implications for tocolytic therapy with oxytocin antagonists. Am J Obstet Gynecol 175(5):1331–1335. https://doi.org/10.1016/S0002-9378(96)70050-9
Steinwall M, Bossmar T, Brouard R et al (2005) The effect of relcovaptan (SR 49059), an orally active vasopressin V1a receptor antagonist, on uterine contractions in preterm labor. Gynecol Endocrinol 20(2):104–109. https://doi.org/10.1080/09513590400021144
Stoev S, Cheng LL, Manning M et al (2001) Design of tocolytic oxytocin antagonists which are more selective than Atosiban in rat bioassays and in human receptor assays. In: Lebl M, Houghten RA (eds) Peptides: The wave of the future, Proceedings of the Seventeenth American Peptide Symposium, San Diego, CA, USA. American Peptide Society, pp 699–700
Manning M, Stoev S, Cheng LL et al (2001) Design of oxytocin antagonists, which are more selective than atosiban. J Pept Sci 7(9):449–465. https://doi.org/10.1002/psc.339
Stymiest JL, Mitchell BF, Wong S et al (2003) Synthesis of biologically active dicarba analogues of the peptide hormone oxytocin using ring-closing metathesis. Org Lett 5(1):47–49. https://doi.org/10.1021/ol027160v
Stymiest JL, Mitchell BF, Wong S et al (2005) Synthesis of oxytocin analogues with replacement of sulfur by carbon gives potent antagonists with increased stability. J Org Chem 70(20):7799–7809. https://doi.org/10.1021/jo050539l
Gimpl G, Postina R, Fahrenholz F et al (2005) Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin. Eur J Pharmacol 510(1–2):9–16. https://doi.org/10.1016/j.ejphar.2005.01.010
Wesley VJ, Hawtin SR, Howard HC et al (2002) Agonist-specific, high-affinity binding epitopes are contributed by an arginine in the N-terminus of the human oxytocin receptor. Biochemistry 41(16):5086–5092. https://doi.org/10.1021/bi015990v
Aurell C-J, Melin P, Nilsson A et al (1995) Preparation of peptides exhibiting oxytocin antagonistic activity. WO9502609A1
Nilsson A, Aurell C-J, Ekholm K et al (1996) Synthesis of an oxytocin antagonist—Ferring F 792. In: Ramage R, Epton R (eds) Peptides 1996, Proceedings of the 24th European Peptide Symposium, Edinburgh, Scotland. Mayflower Scientific, pp 683–684
Wisniewski K, Trojnar J, Riviere P et al (1999) The synthesis of a new class of oxytocin antagonists. Bioorg Med Chem Lett 9(19):2801–2804. https://doi.org/10.1016/s0960-894x(99)00478-3
Wisniewski K, Trojnar J, Haigh R et al (1999) In search for a new class of oxytocin antagonists. In: Bajusz S, Hudecz F (eds) Peptides 1998, Proceedings of the 25th European peptide symposium, Budapest. Akademiai Kiado, pp 518–519
Melin P, Nilsson A, Trojnar J et al (1998) Preparation of heptapeptide alcohol oxytocin analogs. WO9823636A1
Pierzynski P, Lemancewicz A, Reinheimer T et al (2004) Inhibitory effect of barusiban and atosiban on oxytocin-induced contractions of myometrium from preterm and term pregnant women. J Soc Gynecol Investig 11(6):384–387. https://doi.org/10.1016/j.jsgi.2004.02.008
Nilsson L, Reinheimer T, Steinwall M et al (2003) FE 200 440: a selective oxytocin antagonist on the term-pregnant human uterus. BJOG 110(11):1025–1028
Reinheimer TM, Bee WH, Resendez JC et al (2005) Barusiban, a new highly potent and long-acting oxytocin antagonist: pharmacokinetic and pharmacodynamic comparison with atosiban in a cynomolgus monkey model of preterm labor. J Clin Endocrinol Metab 90(4):2275–2281. https://doi.org/10.1210/jc.2004-2120
Thornton S, Goodwin TM, Greisen G et al (2009) The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol 200(6):627 e621–627 e610. https://doi.org/10.1016/j.ajog.2009.01.015
Guttmann S, Boissonnas RA (1963) Synthesis of Ser4-oxytocin, Ala4-oxytocin, Ser5-oxytocin, and Ala5-oxytocin. Helv Chim Acta 46(5):1626–1636
du Vigneaud V, Denning GS Jr, Drabarek S et al (1964) The synthesis and pharmacological study of 4-decarboxamido-oxytocin (4-alpha-aminobutyric acid-oxytocin) and 5-decarboxamido-oxytocin (5-alanine-oxytocin). J Biol Chem 239:472–478
Chan WY, Wo NC, Cheng LL et al (1996) Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor. J Pharmacol Exp Ther 277(2):999–1003
Cheng LL, Olma A, Klis WA et al (1996) Position 5 modifications of vasopressin and oxytocin antagonists enhance OT receptor selectivity. In: PTP K, Hodges RS (eds) Peptides: Chemistry, structure and biology, Proceedings of the 14th American Peptide Symposium, Columbus, OH, USA. Mayflower Scientific, pp 380–381
Manning M, Cheng LL, Stoev S et al (1995) An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin. J Pept Sci 1(1):66–79. https://doi.org/10.1002/psc.310010109
Flouret G, Majewski T, Brieher W et al (1993) Systematic substitution of an oxytocin antagonist with D-amino acids: unexpected high antagonistic potency of the D-Cys6-substituted analogue. J Med Chem 36(6):747–749
Belec L, Maletinska L, Slaninova J et al (2001) The influence of steric interactions on the conformation and biology of oxytocin. Synthesis and analysis of penicillamine(6)-oxytocin and penicillamine(6)-5-tert-butylproline(7)-oxytocin analogs. J Pept Res 58(3):263–273
Belec L, Slaninova J, Lubell WD (2000) A study of the relationship between biological activity and prolyl amide isomer geometry in oxytocin using 5-tert-butylproline to augment the Cys(6)-Pro(7) amide cis-isomer population. J Med Chem 43(8):1448–1455. https://doi.org/jm990090m
Larive CK, Guerra L, Rabenstein DL (1992) Cis/trans conformational equilibrium across the cysteine6-proline peptide bond of oxytocin, arginine vasopressin, and lysine vasopressin. J Am Chem Soc 114(19):7331–7337
Wittelsberger A, Patiny L, Slaninova J et al (2005) Introduction of a cis-prolyl mimic in position 7 of the peptide hormone oxytocin does not result in antagonistic activity. J Med Chem 48(21):6553–6562. https://doi.org/10.1021/jm049205z
Fragiadaki M, Magafa V, Borovickova L et al (2007) Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem 42(6):799–806. https://doi.org/10.1016/j.ejmech.2006.12.016
Hill PS, Smith DD, Slaninova J et al (1990) Bicyclization of a weak oxytocin agonist produces a highly potent oxytocin antagonist. J Am Chem Soc 112(8):3110–3113. https://doi.org/10.1021/ja00164a035
Smith DD, Slaninova J, Hruby VJ (1992) Structure-activity studies of a novel bicyclic oxytocin antagonist. J Med Chem 35(9):1558–1563
Liao S, Shenderovich MD, Zhang Z et al (1998) Substitution of the side-chain-constrained amino acids β-methyl-2',6'-dimethyl-4'-methoxytyrosine in position 2 of a bicyclic oxytocin analogue provides unique insights into the bioactive topography of oxytocin antagonists. J Am Chem Soc 120(29):7393–7394. https://doi.org/10.1021/ja980848b
Manning M, Cheng LL, Klis WA et al (1995) Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists. J Med Chem 38(10):1762–1769
Lebl M (1987) Analogs with dissociated and/or high activities. In: Jost K, Lebl M, Brtnik F (eds) CRC Handbook of neurohypophyseal hormone analogs, vol 2., pt 1. CRC Press, Boca Raton, pp 75–154
Chini B, Fanelli F (2000) Molecular basis of ligand binding and receptor activation in the oxytocin and vasopressin receptor family. Exp Physiol 85(Spec No):59S–66S
du Vigneaud V, Winestock G, Murti VVS et al (1960) Synthesis of 1-beta -mercaptopropionic acid oxytocin (deamino-oxytocin), a highly potent analog of oxytocin. J Biol Chem 235:PC 64–PC 66
Hope DB, Murti VV, Du Vigneaud V (1962) A highly potent analogue of oxytocin, desamino-oxytocin. J Biol Chem 237:1563–1566
Ferrier BM, Jarvis D, Du Vigneaud V (1965) Deamino-oxytocin. Its isolation by partition chromatography on Sephadex and crystallization from water, and its biological activities. J Biol Chem 240(11):4264–4266
Walti M, Hope DB (1972) Synthesis of (1-(L-2-hydroxy-3-mercaptopropanoic acid))oxytocin, a highly potent analogue of oxytocin. J Chem Soc Perkin 1:1946–1950
Hope DB (1974) Pharmacology of hydroxy-analogues of oxytocin. Proc R Soc Med 67(1):40–42
Manning M, Lowbridge J, Sawyer WH et al (1976) Synthesis and some pharmacological properties of [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine]oxytocin (hydroxy [4-Thr]oxytocin), a peptide with strikingly high oxytocic potency and of [1-(L-2-hydroxy-3-mercaptopropanoic acid)]oxytocin (hydroxy-oxytocin). J Med Chem 19(3):376–380
Manning M, Coy E, Sawyer WH (1970) Solid-phase synthesis of (4-threonine)-oxytocin. A more potent and specific oxytocic agent than oxytocin. Biochemistry 9(20):3925–3930
Manning M, Sawyer WH (1970) 4-Threonine-oxytocin: a more active and specific oxytocic agent than oxytocin. Nature 227(5259):715–716
Barth T, Slaninova J, Lebl M et al (1987) Effect of threonine in position 4 in oxytocin and vasotocin analogs on the time course of uterotonic response. Endocrinol Exp 21(3):191–197
Hruby VJ, Upson DA, Yamamoto DM et al (1979) Active site studies of neurohypophyseal hormones. Comparison of oxytocin and arginine vasopressin analogs containing 2-D-tyrosine. J Am Chem Soc 101(10):2717. https://doi.org/10.1021/ja00504a037
Bodanszky M, du Vigneaud V (1959) Synthesis of a biologically active analog of oxytocin, with phenylalanine replacing tyrosine. J Am Chem Soc 81:1258–1259
Konzett H, Berde B (1959) The biological activity of a new analog of oxytocin in which the tyrosyl group is replaced by phenylalanyl. Br J Pharmacol Chemother 14:133–136
Zhuze AL, Jost K, Kasafirek E et al (1964) Amino acids and peptides. XLV. Analogs of oxytocin with O-ethyltyrosine, p-methylphenylalanine, and p-ethylphenylalanine replacing tyrosine. Collect Czechoslov Chem Commun 29(11):2648. https://doi.org/10.1135/cccc19642648
Pliska V, Marbach P, Vasak J et al (1977) [2-o-Iodotyrosine]-oxytocin and [2-o-methyltyrosine]-oxytocin: basic pharmacology and comments on their potential use in binding studies. Experientia 33(3):367–369
Barth T (1977) Chymotryptic cleavage of deamino analogs of oxytocin. Collect Czechoslov Chem Commun 42(1):195–200. https://doi.org/10.1135/cccc19770195
Vilhardt H, Atke A, Barthova J et al (1997) Interaction of chymotrypsin with carbetocin ([1-deamino-1-monocarba-2-O-methyltyrosine]-oxytocin). Pharmacol Toxicol 81(3):147–150
Jost K, Barth T, Krejci I et al (1973) Amino acids and peptides. CXIII. Carba1-oxytocin: synthesis and some of its biological properties. Collect Czechoslov Chem Commun 38(4):1073–1083. https://doi.org/10.1135/cccc19731073
Keller O, Rudinger J (1974) Synthesis of (1,6-alpha,alpha'-diaminosuberic acid)oxytocin ('dicarba-oxytocin'). Helv Chim Acta 57(5):1253–1259. https://doi.org/10.1002/hlca.19740570502
Muttenthaler M, Andersson A, de Araujo AD et al (2010) Modulating oxytocin activity and plasma stability by disulfide bond engineering. J Med Chem 53(24):8585–8596. https://doi.org/10.1021/jm100989w
Pliska V, Jutz G, Beck S (1985) Molecular sites of oxytocin inactivation in the rat uterus: in vitro investigation with enzyme probes using oil-immersion technique. In: Deber CM, Hruby VJ, Kopple KD (eds) Peptides: structure and function. Proceedings of the ninth American Peptide Symposium, Toronto, Canada. Pierce Chemical Company, pp 603–606
Rudinger J, Jost K (1964) A biologically active analogue of oxytocin not containing a disulfide group. Experientia 20(10):570–571
Barth T, Krejci I, Kupkova B et al (1973) Pharmacology of cyclic analogues of deamino-oxytocin not containing a disulphide bond (carba analogues). Eur J Pharmacol 24(2):183–188
Barth T, Krejci I, Vaneckova J et al (1974) Prolonged action of deamino-carba analogues of oxytocin on the rat uterus in vivo. Eur J Pharmacol 25(1):67–70
Fric I, Kodicek M, Prochaszka Z et al (1974) Amino acids and peptides. CXXI. Synthesis and circular dichroism of some deamino-1-carbaoxytocin analogs with modifications of the amino acid residue at position 2. Collect Czechoslov Chem Commun 39(5):1290–1302. https://doi.org/10.1135/cccc19741290
Engstrom T, Barth T, Melin P et al (1998) Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation. Eur J Pharmacol 355(2–3):203–210
Barth T, Slaninova J, Lebl M et al (1980) Biological activities and protracted action of carba-analogs of deamino-oxytocin with O-methyltyrosine in position 2. Collect Czechoslov Chem Commun 45(11):3045–3050. https://doi.org/10.1135/cccc19803045
Hunter DJ, Schulz P, Wassenaar W (1992) Effect of carbetocin, a long-acting oxytocin analog on the postpartum uterus. Clin Pharmacol Ther 52(1):60–67
Peters NC, Duvekot JJ (2009) Carbetocin for the prevention of postpartum hemorrhage: a systematic review. Obstet Gynecol Surv 64(2):129–135. https://doi.org/10.1097/OGX.0b013e3181932e5b
Rath W (2009) Prevention of postpartum haemorrhage with the oxytocin analogue carbetocin. Eur J Obstet Gynecol Reprod Biol 147(1):15–20. https://doi.org/10.1016/j.ejogrb.2009.06.018
Attilakos G, Psaroudakis D, Ash J et al (2010) Carbetocin versus oxytocin for the prevention of postpartum haemorrhage following caesarean section: the results of a double-blind randomised trial. BJOG 117(8):929–936. https://doi.org/10.1111/j.1471-0528.2010.02585.x
Meshykhi LS, Nel MR, Lucas DN (2016) The role of carbetocin in the prevention and management of postpartum haemorrhage. Int J Obstet Anesth 28:61–69. https://doi.org/10.1016/j.ijoa.2016.10.003
Danglas P, Reidy M, Korner P et al (2016) Method of treating Prader-Willi syndrome using oxytocin receptor agonists. WO2016044131
Leonard AK, Sestak JO, Costantino HR et al (2012) Intranasal carbetocin formulations and methods for the treatment of autism. US20120172304
Frank W (1964) Syntheses of selenium-containing peptides. 3. Diseleno-oxytocin. Hoppe Seylers Z Physiol Chem 339(1):222–229
Walter R, Chan W-Y (1967) Syntheses and pharmacological properties of selenium isologs of oxytocin and deaminooxytocin. J Am Chem Soc 89(15):3892–3898. https://doi.org/10.1021/ja00991a037
Walter R, du Vigneaud V (1965) 6-Hemi-L-selenocystine-oxytocin and 1-deamino-6-hemi-L-selenocystine-oxytocin, highly potent isologs of oxytocin and 1-deaminooxytocin. J Am Chem Soc 87(18):4192–4193. https://doi.org/10.1021/ja01096a036
Walter R, du Vigneaud V (1966) 1-Deamino-1,6-L-selenocystineoxytocin; a highly potent isolog of 1-deaminooxytocin. J Am Chem Soc 88(6):1331–1332. https://doi.org/10.1021/ja00958a053
de Araujo AD, Mobli M, Castro J et al (2014) Selenoether oxytocin analogues have analgesic properties in a mouse model of chronic abdominal pain. Nat Commun 5:3165. https://doi.org/10.1038/ncomms4165
Muttenthaler M, Andersson A, Vetter I et al (2017) Subtle modifications to oxytocin produce ligands that retain potency and improved selectivity across species. Sci Signal 10(508). https://doi.org/10.1126/scisignal.aan3398
Ferrier BM, Vd V (1966) 9-Deamidooxytocin, an analog of the hormone containing a glycine residue in place of the glycinamide residue. J Med Chem 9(1):55–57. https://doi.org/10.1021/jm00319a014
Smith CW, Walter R, Moore S et al (1978) Replacement of the disulfide bond in oxytocin by an amide group. Synthesis and some biological properties of (cyclo-(1-L-aspartic acid,6-L-alpha,beta-diaminopropionic acid))oxytocin. J Med Chem 21(1):117–120
Bissantz C, Bleicher K, Grundschober C (2014) Peptides as oxytocin receptor agonists and their use in treatment of mental and behavioral disorders. WO2014095773
Bissantz C, Bleicher K, Grundschober C (2015) Peptides as oxytocin receptor agonists and their use in treatment of mental and behavioral disorders. WO2015185467
Bleicher K, Cueni A, Puentener K et al (2016) Preparation of oxytocin analogs as oxytocin receptor agonists and their use in treatment of neurological disorders. WO2016020349A1
Adachi Y, Sakimura K, Shimizu Y et al (2017) Potent and selective oxytocin receptor agonists without disulfide bridges. Bioorg Med Chem Lett 27(11):2331–2335. https://doi.org/10.1016/j.bmcl.2017.04.030
Bissantz C, Bleicher K, Chakraborty K et al (2016) Peptides as oxytocin receptor agonists and their use in treatment of mental and behavioral disorders. WO2015185584
Lebl M, Barth T, Jost K (1978) Amino acids and peptides. Part CIL. Synthesis, reduction, and pharmacological properties of the sulfoxides of some carba-analogs of oxytocin. Collect Czechoslov Chem Commun 43(6):1538. https://doi.org/10.1135/cccc19781538
Smith CW, Ferger MF (1976) Synthesis and some pharmacological properties of five analogs of oxytocin having L-homocysteine in position 6. J Med Chem 19(2):250–254
Chen L, Zoulikova I, Slaninova J et al (1997) Synthesis and pharmacology of novel analogs of oxytocin and deaminooxytocin: directed methods for the construction of disulfide and trisulfide bridges in peptides. J Med Chem 40(6):864–876
Bodanszky M, Bath RJ (1968) Hindered amines in peptide synthesis. Synthesis of 7-glycine-oxytocin. Chem Commun (13):766–767
Bespalova ZD, Martynov VF, Titov MI (1968) New analogs of oxytocin, 7-glycineoxytocin and 7-D-leucineoxytocin. Zh Obshch Khim 38(8):1684–1687
Walter R, Smith CW, Roy J et al (1976) Oxytocin analogues with combined high smooth muscle and negligible antidiuretic activities. Investigation of position 7 in neurohypophyseal hormones. J Med Chem 19(6):822–825
Walter R, Yamanaka T, Sakakibara S (1974) A neurohypophyseal hormone analog with selective oxytocin-like activities and resistance to enzymatic inactivation: an approach to the design of peptide drugs. Proc Natl Acad Sci U S A 71(5):1901–1905
Grzonka Z, Lammek B, Gazis D et al (1983) Synthesis and some pharmacological properties of [4-threonine,7-sarcosine]oxytocin, a peptide with high oxytocic potency, and of [4-threonine,7-N-methylalanine]oxytocin. J Med Chem 26(12):1786–1787
Grzonka Z, Lammek B, Kasprzykowski F et al (1983) Synthesis and some pharmacological properties of oxytocin and vasopressin analogues with sarcosine or N-methyl-L-alanine in position 7. J Med Chem 26(4):555–559
Lowbridge J, Manning M, Haldar J et al (1977) Synthesis and some pharmacological properties of [4-threonine, 7-glycine]oxytocin, [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine, 7-glycine]oxytocin (hydroxy[Thr4, Gly7]oxytocin), and [7-Glycine]oxytocin, peptides with high oxytocic-antidiuretic selectivity. J Med Chem 20(1):120–123
Tence M, Guillon G, Bottari S et al (1990) Labelling of vasopressin and oxytocin receptors from the human uterus. Eur J Pharmacol 191(3):427–436. https://doi.org/0014-2999(90)94177-Y
Mihai R, Coculescu M, Wakerley JB et al (1994) The effects of [Arg8]vasopressin and [Arg8]vasotocin on the firing rate of suprachiasmatic neurons in vitro. Neuroscience 62(3):783–792
Guillon G, Derick S, Pena A et al (2004) The discovery of novel vasopressin V1b receptor ligands for pharmacological, functional and structural investigations. J Neuroendocrinol 16(4):356–361. https://doi.org/10.1111/j.0953-8194.2004.01163.x
Wisniewski K, Galyean R, Tariga H et al (2011) New, potent, selective, and short-acting peptidic V1a receptor agonists. J Med Chem 54(13):4388–4398. https://doi.org/10.1021/jm200278m
Rosamond JD, Ferger MF (1976) Synthesis and some pharmacological properties of oxytocin analogues having L-thiazolidine-4-carboxylic acid in position 7. J Med Chem 19(7):873–876
Grzonka Z, Mishra PK, Bothner-By AA (1985) Conformational preferences and binding to neurophysins of oxytocin analogs with sarcosine or N-methylalanine in position 7. Int J Pept Protein Res 25(4):375–381
Sawyer WH, Manning M (1971) 4-Threonine analogues of neurohypophysial hormones with selectively enhanced oxytocin-like activities. J Endocrinol 49(1):151–165
Rimpler M, Schoeberl A (1969) Synthesis of nonapeptide with oxytocin activity. Naturwissenschaften 56(12):638
Rimpler M (1971) [1-Deamino]lysinevasotocin, a disulfide polypeptide exhibiting oxytocin activity. Justus Liebigs Ann Chem 745:8–19
Surovec D, Hoffman PL, Walter R (1974) Comparison of some biological activities of arginine vasotocin and synthetic analogs. Experientia 30(7):823–824
Chini B, Chinol M, Cassoni P et al (2003) Improved radiotracing of oxytocin receptor-expressing tumours using the new [111In]-DOTA-Lys8-deamino-vasotocin analogue. Br J Cancer 89(5):930–936. https://doi.org/10.1038/sj.bjc.6601189
Busnelli M, Kleinau G, Muttenthaler M et al (2016) Design and characterization of superpotent bivalent ligands targeting oxytocin receptor dimers via a channel-like structure. J Med Chem 59(15):7152–7166. https://doi.org/10.1021/acs.jmedchem.6b00564
Hlavacek J, Fric I (1989) Amino acids and peptides. Part CCXIII. The effect of non-coded amino acids on the degradation of oxytocin analogs with α-chymotrypsin. Collect Czechoslov Chem Commun 54(8):2261. https://doi.org/10.1135/cccc19892261
Sciabola S, Goetz GH, Bai G et al (2016) Systematic N-methylation of oxytocin: Impact on pharmacology and intramolecular hydrogen bonding network. Bioorg Med Chem 24(16):3513–3520. https://doi.org/10.1016/j.bmc.2016.05.062
Choc MG (1997) Bioavailability and pharmacokinetics of cyclosporine formulations: Neoral vs Sandimmune. Int J Dermatol 36(Suppl 1):1–6
Goetz GH, Farrell W, Shalaeva M et al (2014) High throughput method for the indirect detection of intramolecular hydrogen bonding. J Med Chem 57(7):2920–2929. https://doi.org/10.1021/jm401859b
Urry DW, Walter R (1971) Proposed conformation of oxytocin in solution. Proc Natl Acad Sci U S A 68(5):956–958
Ohno A, Kawasaki N, Fukuhara K et al (2010) Complete NMR analysis of oxytocin in phosphate buffer. Magn Reson Chem 48(2):168–172. https://doi.org/10.1002/mrc.2557
Ashworth DM, Batt AR, Baxter AJ et al (2006) Nonpeptide oxytocin agonists. Drugs Future 31(4):345–353
Kablaoui N, Vanase-Frawley M, Sciabola S (2018) Hybrid peptide-small molecule oxytocin analogs are potent and selective agonists of the oxytocin receptor. Bioorg Med Chem Lett 28(3):415–419. https://doi.org/10.1016/j.bmcl.2017.12.027
Breton C, Haenggeli C, Barberis C et al (2002) Presence of functional oxytocin receptors in cultured human myoblasts. J Clin Endocrinol Metab 87(3):1415–1418. https://doi.org/10.1210/jcem.87.3.8537
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Wiśniewski, K. (2019). Design of Oxytocin Analogs. In: Goetz, G. (eds) Cyclic Peptide Design. Methods in Molecular Biology, vol 2001. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9504-2_11
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9504-2_11
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9503-5
Online ISBN: 978-1-4939-9504-2
eBook Packages: Springer Protocols